http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111999424-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-8813 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N30-88 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-88 |
| filingDate | 2017-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111999424-B |
| titleOfInvention | Subclinical pelvic inflammatory disease markers and their use |
| abstract | The invention belongs to the field of biotechnology, and relates to a series of metabolites used in the diagnosis of subclinical pelvic inflammatory disease. The present invention systematically screens metabolites in blood through a metabolomics method based on liquid chromatography-mass spectrometry, and finds metabolites that are significantly correlated with the occurrence of subclinical pelvic inflammatory disease as biomarkers of the disease. The metabolites include: lysophosphatidic acid 16:0/0:0, 1-phosphoceramide d18:1/16:0, stearamide, linoleic acid, stearic acid, phosphatidylethanolamine P-18: 0/0:0, Phosphatidylethanolamine P‑18:0/0:0, Lysophosphatidylethanolamine P‑20:0/0:0, Indole Sulfate, 3‑Indolepropionic Acid, p‑Cresol . The biomarkers found in the present invention can be used for the non-invasive diagnosis and indicated treatment of subclinical pelvic inflammatory disease, and have obvious advantages compared with the clinical method that requires surgery for diagnosis. |
| priorityDate | 2017-08-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 50.